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Thrombopoietin (TPO) is a humoral growth factor originally identiﬁed for its ability to stimulate the proliferation and
diﬀerentiation of megakaryocytes. In addition to its actions on thrombopoiesis, TPO directly modulates the homeostatic potential
of mature platelets by inﬂuencing their response to several stimuli. In particular, TPO does not induce platelet aggregation per se
but is able to enhance platelet aggregation in response to diﬀerent agonists (“priming eﬀect”). Our research group was actively
involved, in the last years, in characterizing the eﬀects of TPO in several human critical diseases. In particular, we found that
TPO enhances platelet activation and monocyte-platelet interaction in patients with unstable angina, chronic cigarette smokers,
and patients with burn injury and burn injury complicated with sepsis. Moreover, we showed that TPO negatively modulates
myocardial contractility by stimulating its receptor c-Mpl on cardiomyocytes and the subsequent production of NO, and it
mediates the cardiodepressant activity exerted in vitro by serum of septic shock patients by cooperating with TNF-α and IL-1β.
This paper will summarize the most recent results obtained by our research group on the pathogenic role of elevated TPO levels in
these diseases and discuss them together with other recently published important studies on this topic.
1.Introduction
Thrombopoietin (TPO) is a humoral growth factor original-
ly identiﬁed using antisense oligonucleotides to c-mpl [1], a
protooncogenethatisthehumanhomologofv-mpl,theviral
oncogene responsible for the transforming myeloprolifera-
tive leukemia virus (MPLV) [2]. Initial characterization of
c-Mpl-deﬁcient mice showed that they have severe throm-
bocytopenia but relatively normal levels of other hemato-
logical cell types [3]. Subsequently, several research groups
identiﬁed TPO as the primary ligand for the c-Mpl receptor
[4–10] and TPO/Mpl signal transduction was shown to play
critical roles in thrombopoiesis, from ex vivo megakaryocyte
progenitor expansion and diﬀerentiation to in vivo platelet
production [4–11].
TPO is constitutively produced in the liver and kidneys
and is then cleared from circulation upon binding with its
receptor c-Mpl [7, 8]. Upon TPO binding, c-Mpl receptors
undergo homodimerization to initiate intracellular signal-
ing, including activation of the JAK2/signal transducers and
activators of transcription (STAT) pathway [12].
In addition to its role in thrombopoiesis, TPO also plays
a role in expanding erythroid and granulocytic-monocytic
progenitors [13], and loss of TPO/Mpl signaling was asso-
ciated to a potential defect in the multipotent cell compart-
ment or even in the stem cell compartment [14, 15]. Subse-
quent studies clearly deﬁned the role of TPO in expanding or
maintaining the pool of transplantable hematopoietic stem
cells, further establishing the responsiveness of cells in the
primitive hematopoietic compartment to this cytokine sig-
naling pathway [16, 17].
Elevated plasma TPO levels have been reported in diﬀer-
ent clinical conditions, including several hematological dis-
eases usually associated with thrombocytopenia, where in-
creased circulating TPO may be a response to altered bone
marrow hematopoiesis or bone marrow failure [18–20]. Of2 Mediators of Inﬂammation
Table 1: List of publications describing biological functions of
TPO/c-MPL system apart from hematopoietic mechanisms.
Mature platelets [12, 25, 30–32, 64, 72, 109–118]
Polymorphonuclear leukocytes [86, 119, 120]
Endothelial cells [96–99, 121, 122]
Cardiac cells [85, 100–102]
Brain cells [70, 123–127]
Ovarian cells [128]
Cancer cells [129, 130]
particular importance is the example of immune throm-
bocytopenia, a disorder characterized by immune-mediated
plateletdestructionandimpairedplateletproduction,result-
ing in platelet count lower than 100,000 per cubic millimeter
and varying degrees of bleeding risk [21]. In patients with
immune thrombocytopenia, indeed, TPO levels are usually
normal or only slightly increased for reasons that remain un-
clear [19, 22]. This observation led to the concept of treating
the disorder by means of exogenous stimulation of TPO
receptors and to the development of TPO-receptor agonists,
whose clinical use was recently approved for adult patients
aﬀected by immune thrombocytopenia at risk for bleeding
[21, 23].
Besides hematological diseases, elevated circulating TPO
levelshavebeenalsoreportedinotherclinicalconditions,in-
cluding critical diseases such as acute coronary syndromes
[24, 25] and sepsis [26–29]( Table 1). This paper will sum-
marize the most recent results obtained by our research
group on the pathogenic role of elevated TPO levels in these
diseases and discuss them together with other recently pub-
lished important studies on this topic.
2. Effects of Thrombopoietin on
PlateletActivation
Shortly after the cloning and characterization of TPO as c-
Mpl ligand, we and others have shown that the TPO recep-
tors are expressed by mature platelets and that TPO direct-
ly modulates the homeostatic potential of platelets by in-
ﬂuencing their response to several stimuli [30, 31]. In par-
ticular TPO does not induce platelet aggregation per se,
both in platelet-rich plasma and in whole blood, but is
able to enhance platelet aggregation in response to diﬀerent
agonists (“priming eﬀect”) [30, 31]. In addition, TPO stim-
ulatesplatelet-leukocyteassociationsinwholebloodthrough
expression of platelet P-selectin [32]. The characterization of
this “priming eﬀect” prompted us to study the pathophys-
iological eﬀects of plasma TPO in those clinical conditions
where TPO levels are increased and platelet activation has a
pathogenic role.
3.Thrombopoietin IncreasesPlatelet
ActivationinPatientswith Unstable Angina
It is known that patients with unstable angina (UA)
have hypersensitive platelets, increased levels of circulating
platelet aggregates and platelet secretory products [33–37];
theyalsoshowincreasedplatelet-leukocyteaggregates,which
have been proposed to represent a better reﬂection of plaque
instability and ongoing vascular thrombosis and inﬂamma-
tion [38, 39]. Activated platelets deposit indeed at sites of
unstable plaque rupture and may potentiate thrombus for-
mation, precipitating or exacerbating coronary vascular ob-
struction [35]. The clinical eﬃcacy of antiplatelet therapies
also conﬁrms the importance of platelets in acute coronary
syndromes [40]; however, their incomplete eﬀectiveness sug-
gests that alternative platelet activation pathways may be
important [40].
Higher levels of TPO were previously reported by Sen-
aran and colleagues [24] in patients with acute coronary syn-
dromes than control subjects and shown to correlate with
plateletsize,thuspotentiallyresultinginhemostaticallymore
active platelets [24].
In our study [25], we enrolled 15 patients with unstable
angina (UA) and, as controls, 15 patients with stable angina
(SA) and 15 healthy subjects. We measured circulating levels
of TPO by ELISA and of C-reactive protein (CRP) by im-
munoturbidimetric assay, as well as ex vivo monocyte-plate-
let binding and the platelet expression of P-selectin and of
the TPO receptor, c-Mpl, by ﬂow cytometry [41]. Finally,
the priming activity of patient or control plasma on platelet
aggregation and monocyte-platelet binding [25] and the role
of TPO in this eﬀect were also studied in vitro.
Conﬁrming what was previously reported by others [24],
we found higher circulating TPO levels in patients with UA,
at the time of hospital admission, than in patients with SA or
healthy controls [25]. Of note, we enrolled the UA patients
in the emergency room, before any therapeutic intervention
wasstarted,andwethereforebelievethatourdatamayclose-
ly reﬂect the ongoing pathogenic events leading to the devel-
opment of UA.
Elevation of TPO in the plasma of patients with UA was
also indirectly conﬁrmed by the ﬁnding of reduced surface
expression of c-Mpl on circulating platelets, whereas no such
a change was detected in patients with SA or healthy con-
trols [25]. Receptor-mediated internalization is indeed con-
sidered the primary mean of regulating plasma TPO levels
[42, 43]. Diminished c-Mpl expression in platelets from UA
patients may thus depend on the previous binding of TPO to
itsreceptorinvivo,followedbyitsinternalizationandsurface
downregulation [42, 43]. In addition, the in vitro stimu-
lation with recombinant human TPO (rhTPO) was able
to phosphorylate c-Mpl only in platelets from SA patients
and healthy controls, but not in those from UA patients, fur-
ther sustaining this hypothesis [25]. This same mechanism
was previously shown for thrombocytopenic mice [44]a n d
humans with the syndrome of congenital thrombocytopenia
with absent radii [45], whose platelets are exposed, in vivo to
increased levels of endogenous TPO.
Decreasedsurfacelevelsofc-Mpltogetherwithdecreased
platelet sensitivity to exogenous stimulation in vitro with
a pegylated N-terminal domain of human TPO (PEG-
rHuMGDF) have also been evoked as a “protective” mech-
anism against the prothrombotic eﬀects of in vivo treat-
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microthrombosis[46];however,theconclusionsofthisstudy
refer only to thrombocytopenic states, in which endogenous
TPO levels are elevated [44–46], whereas this and our sub-
sequent studies were addressed to speciﬁc pathologic condi-
tions in which TPO levels rise in presence of normal plate-
let counts. The precise origin of the rise in plasma TPO level
in UA patients remains unclear. We found that CRP levels
were increased in this study group, suggesting that the liver
acute-phase response, which takes place in acute coronary
syndromes[47–49],mayhavearoleinincreasingTPOlevels.
Considering the evidence that elevated CRP has independent
prognostic value in UA [50, 51], it is tempting to speculate
that the negative prognostic implications of high CRP levels
in patients with UA may be at least partially related to the
concomitant increase in TPO production and subsequent
priming of platelet aggregation. However, activated platelets
could also represent a major contributor to the elevated TPO
levels observed in UA patients, since they are known to
release full-length biological active TPO upon stimulation
[52]. In addition, platelet alpha-granular proteins may in-
creaseTPOgeneexpressionandconsequentTPOproduction
in bone marrow stromal cells via a feed-back mechanism
[53, 54].
In addition to elevated plasmatic concentrations of TPO,
patients with UA also showed increased indexes of ex vivo
platelet activation, such as monocyte-platelet binding and
platelet P-selectin expression [25].
The presence of TPO in the circulation precludes the
evaluationofitsroleonplateletaggregationdirectlyonblood
samples obtained from patients. Therefore, we studied the
contribution of TPO to platelet aggregation by adding pa-
tient plasma samples to platelets of healthy subjects in vitro
and inhibiting TPO biological activity by using a TPOR-Fc
chimera synthesized in our laboratory [25]. In these exper-
imental conditions, plasma from patients with UA, but not
from SA patients or healthy controls, markedly enhances
platelet aggregation as well as monocyte-platelet binding in
bloodsamplesfromhealthydonors,stressingtheimportance
of elevated TPO concentrations in the pathogenesis of in-
creased platelet aggregation in UA [25]. Several data show
that the “priming eﬀect” exerted by plasma samples from
patients with UA may be due to their content in TPO: (1)
the priming eﬀect induced by plasma from UA patients was
signiﬁcantly decreased when TPO activity was inhibited with
the TPOR-Fc chimera; and (2) adjusting the concentrations
of TPO in plasma from SA patients to those measured in
UA patients by adding exogenous rhTPO induced a signiﬁ-
cant increase of the priming eﬀect, similar to that observed
with plasma from patients with UA, on ADP- or EPI-in-
duced aggregation in PRP. In vivo, a similar “priming eﬀect”
induced by TPO on platelet activation has also been docu-
mented in nonhuman primates; platelets derived from TPO-
treated animals showed indeed a heightened sensitivity to
substances that stimulate platelet aggregation during the ﬁrst
few days of treatment [55].
PlasmafromUApatientsalsoinducedasigniﬁcantprim-
ing eﬀect on platelet aggregation in the presence of acetylsal-
icylic acid or in PRP from healthy subjects after one-week
oral acetylsalicylic acid treatment [25]. These results suggest
that the activation pathway triggered by TPO is only partially
aﬀected by the antiplatelet therapy commonly used in pa-
tients with myocardial ischemia [40] and that platelet prim-
ing by TPO may represent a mechanism leading to therapeu-
tic failure of antiplatelet agents. Moreover, the phenomenon
wedescribedinthisstudymayprovidetherationaleformore
aggressive (double or triple) antiplatelet treatment in pa-
tients with acute coronary syndromes.
Inconclusion,inthisstudyweshowedthatelevatedlevels
ofcirculatingTPOmayenhanceplateletactivationandmon-
ocyte-platelet interaction in the early phases of UA [25].
Our ex vivo and in vitro ﬁndings suggest an important link
betweencirculatingTPOlevelandthepro-inﬂammatoryand
prothrombotic state that occurs in UA patients and implicate
TPOinthepathogenesisofacutecoronarysyndromes,where
it could potentially precipitate conditions of clinical instabil-
ity.
4.Thrombopoietin IncreasesPlatelet
ActivationinCigaretteSmokers
Chronic smoking is a major risk factor for the development
of atherosclerosis and thrombosis, and it has been strongly
associated with adverse cardiovascular eﬀects [56]. In par-
ticular, enhanced platelet aggregability and subsequent alter-
ations in the clotting cascade have been evoked [57, 58]
as main pathogenic factors sustaining the increased risk of
coronary artery thrombosis in long-term smokers [57, 59].
Sinceinﬂammationplaysacentralroleinthepathogenesisof
atherosclerosis and its complications [60] ,an u m b e ro fs t u d -
ies have investigated the association between smoking and
increase in several inﬂammatory markers, such as CRP [61],
interleukin (IL)-6 [62], tumor necrosis factor (TNF)-α [62],
and CD40L [63]. However, the biological mechanisms link-
ing smoking and atherosclerosis are complex and have not
been fully elucidated.
In our study [64], we evaluated TPO and CRP levels,
platelet-leukocyte binding and the platelet expression of
P-selectin, and the priming activity of smoker or control
plasma on in vitro platelet-monocyte binding in 20 healthy
cigarette smokers and 20 age- and gender-matched non-
smokers. In a second phase of the study we investigated the
eﬀects of acute smoking and of smoking cessation on TPO
levels and ex vivo platelet activation markers [64]. For this
purpose, healthy non-smoking subjects were studied at the
baseline and after they smoked two cigarettes in 30 minutes.
Moreover, 8 healthy cigarette smokers were studied at the
baseline and after they had quit smoking for three weeks.
In the ﬁrst part of this study, we found that chronic
smokers have higher circulating TPO levels than nonsmok-
ers and higher platelet-leukocyte binding and platelet P-
selectin expression ex vivo [64]. Although cigarette smokers
had signiﬁcantly higher TPO levels than nonsmokers, the
concentrations measured in both groups were lower than
those measured in patients with UA [25] and, may someway
be considered within the “physiological” range (i.e., in our
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In addition to elevated plasmatic concentrations of TPO,
cigarette smokers also showed increased indices of ex vivo
platelet activation, such as higher platelet-monocyte binding
and platelet P-selectin expression [64]. Moreover, TPO levels
correlated with ex vivo platelet-monocyte aggregation and P-
selectin expression [64].
In vitro, plasma from cigarette smokers, but not from
nonsmoking subjects, signiﬁcantly enhanced platelet-mon-
ocyte binding in blood samples from healthy donors [64].
The contribution of TPO to this priming eﬀect is suggested
bythecorrelationanalysisshowingthatTPOlevelsandplate-
let-monocyte adhesion in whole blood consensually in-
creased in the two groups. Moreover, the direct proof that
TPOparticipatestotheplateletactivationobservedinchron-
ic smokers is provided by the inhibitory eﬀect of the TPOR-
Fc chimera [64]. Taken together, our data support the hy-
pothesis that circulating TPO may facilitate platelet acti-
vation in smokers by sensitizing platelets to the action of
other agonists. Therefore, it can be suggested that TPO is
required, but is not suﬃcient per se to promote aggregate
formation, and cooperates with other mediators to induce
the observed changes on platelet activation in chronic smok-
ers. Interestingly, TPO primes platelet-monocyte binding in
chronic smokers even in the presence of increased levels
of CRP, which is known to inhibit platelet aggregation and
platelet capture of leukocytes [65]. On the contrary, plasma
samples from cigarette smokers did not induce a signiﬁcant
primingeﬀectonplateletaggregationbothinPRPandwhole
blood. This discrepancy with the results obtained using ﬂow
cytometry may depend on the diﬀerent sensitivity of these
techniques.
Since smoking may also “acutely” aﬀect platelet function
[66], we evaluated whether “acute” smoking (two cigarettes
in the previous 30 minutes) was able to induce an increase in
TPOlevelsandplateletactivation.Wefoundthatthechanges
in TPO levels upon “acute” smoking, in our experimental
conditions, were about a half of the increase observed in
chronic smokers compared with non-smoking controls [64].
However, this TPO elevation did not aﬀect ex vivo platelet
activation, evaluated in terms of platelet-leukocyte adhesion
and P-selectin expression [64]. These results suggest that
transient platelet activation and consequent TPO release by
activated platelets induced by “acute” smoking have only a
negligible role in causing the increase in platelet activation
markers observed in long-term smokers. In addition, “acute”
smoking plasma failed to promote EPI-induced platelet-
leukocyte binding and P-selectin expression in in vitro exper-
iments [64]. This result can be due to several reasons: (a)
the short exposure of the subjects to cigarette smoking (all of
themwerenotusualsmokers),(b)therelativelylowamounts
of TPO released after “acute” smoking, which are further
dilutedintheinvitroexperiments,andalso(c)thelackofthe
concomitant presence of other factors which can be released
after chronic exposure to smoking and cooperate with TPO
in enhancing platelet activation.
Alternatively, higher TPO levels in chronic smokers may
depend on increased hepatic synthesis, sustained by the liver
acute-phase response that takes place in inﬂammatory
diseases,including atherosclerosis[60].ItisknownthatIL-6,
the main acute-phase reactant produced in the liver, enhan-
ces TPO synthesis [67]. The ﬁndings that chronic smokers
have elevated CRP concentrations and that CRP increases
concomitantly with TPO would be in agreement with this
hypothesis. However, in our study, we were not able to docu-
ment a concomitant decrease in TPO and CRP concentra-
tions after smoking cessation [64], and we have no direct
data sustaining the hepatic origin of TPO in our subjects.
Therefore, the precise origin of the rise in plasma TPO level
observed in cigarette smokers remains unclear.
Further stressing the importance of chronic exposure to
smoking products in the genesis of platelet function abnor-
malities, chronic cigarette smokers who quit smoking for
three weeks showed a signiﬁcant decrease in TPO levels,
which was associated with reduced platelet-monocyte and
platelet-granulocyte bindings [64]. Consistently, plasma
drawn after smoking cessation induced a signiﬁcantly lower
platelet-monocyte aggregation in vitro compared to that
induced by plasma obtained before smoking cessation [64].
On the contrary, no diﬀerences in platelet-granulocyte adhe-
sion and P-selectin expression were observed [64].
In conclusion, the results of this study suggest that TPO
may contribute to enhance platelet activation and platelet-
monocyte cross-talk in cigarette smokers and that increased
TPO may represent a novel pathogenic mechanism whereby
cigarette smoking promotes atherogenesis and is associated
with the development of adverse cardiovascular events [64].
5.Thrombopoietin IncreasesPlatelet
ActivationinPatientswithBurnInjury
andBurnInjuryComplicated with Sepsis
Several investigations show that dysregulation of the TPO/
Mpl receptor system is also present in sepsis. In particular,
elevated TPO levels have been reported in healthy volunteers
after endotoxin infusion [28], as well as in septic children
and neonates [26, 68–71] and septic adult patients [27, 29].
More recently, Zakynthinos and colleagues showed that TPO
levels are greatly increased in patients with sepsis compared
to control subjects and correlate with sepsis severity and that
sepsis severity represents the major determinant of elevated
TPO levels in these patients [29]. To investigate the potential
contribution of elevated TPO levels in platelet activation
during burn injury complicated or not by sepsis, we studied
22 burned patients, 10 without and 12 with sepsis, and 10
healthy subjects [72]. We measured plasma levels of TPO, as
well as leukocyte-platelet binding and P-selectin expression
in vivo, and assessed the “priming” activity of plasma from
burned patients or healthy subjects on platelet aggregation
and leukocyte-platelet binding and the involvement of TPO
in these eﬀects in vitro [72].
In this study we found that burn injury is associated with
a signiﬁcant increase in the circulating levels of TPO, about
twofold the levels measured in healthy subjects [72]. TPO
levels further increase upon development of sepsis, suggest-
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may contribute to increase circulating TPO levels in these
patients [72]. These results are substantially in agreement
with those already reported by Zakynthinos and colleagues
in a larger population of patients with sepsis [29].
We also found that patients with burn injury show in-
creased monocyte-platelet aggregates and platelet P-selectin
expression, compared to healthy subjects [72]. In addition,
monocyte-platelet aggregates were signiﬁcantly higher in
burned patients with sepsis than burned patients without
sepsis [72]. These ﬁndings showed that increased platelet ac-
tivation (i.e., P-selectin expression) and heterotypic aggre-
gation (i.e., monocyte-platelet adhesion) also occur in burn
injury, especially after sepsis development, suggesting that
activated platelets ampliﬁes the inﬂammatory reactions and
favor the insurgence of organ damage in these pathological
conditions.
The precise origin of the rise in TPO levels observed in
burned patients without and with sepsis remains unclear.
TPOlevelsarewellknowntobeprimarilyregulatedbyplate-
let mass [73–75], and yet we did not detect thrombocytope-
nia in septic patients in our study. Burned patients without
andwithsepsisalsoshowedincreasedindicesofinvivoplate-
let activation compared to healthy subjects. Moreover, we
found a positive correlation between (a) TPO levels and
monocyte-platelet binding in vivo and (b) TPO levels and
platelet P-selectin expression in vivo. Therefore, platelets
themselves may represent a major contributor to increased
TPO levels, or high TPO levels in burned and septic patients
may depend on increased hepatic synthesis.
Analogously to previous studies, we studied the contri-
bution of TPO to platelet aggregation by adding patient plas-
ma samples to platelets of healthy subjects in vitro and inhib-
iting TPO biological activity by using the TPOR-Fc chimera
[72]. In these experimental conditions, plasma from burned
patients without and with sepsis, but not from healthy sub-
jects, enhances platelet aggregation as well as monocyte-
platelet binding and platelet P-selectin expression in blood
samples from healthy donors [72]. The “priming eﬀect” in-
duced by plasma from burned patients with sepsis was sig-
niﬁcantly higher than that induced by plasma from burned
patients without sepsis in all the experimental conditions
tested [72]. The contribution of TPO to the “priming eﬀect”
exerted by plasma samples from burned patients without
and with sepsis is suggested by (1) the correlation analysis
showingthatTPOlevelsandADP-andEPI-inducedpriming
index in PRP and whole blood consensually increased in
the three groups; (2) the inhibitory eﬀect of the TPOR-Fc
chimera [72]. Taken together, our in vivo and in vitro data
support the hypothesis that TPO present in the circulation
of burned patients, especially those developing sepsis, may
facilitateplateletactivationbysensitizingcirculatingplatelets
to the action of other agonists, thus precipitating the oc-
currence of microvascular thrombosis and the clinical onset
of multiorgan failure.
In conclusion, increased TPO levels may enhance platelet
activation during burn injury and sepsis and have a role in
the pathogenesis of multiorgan failure in these pathological
conditions.
6. Effects of Thrombopoietin on Myocardial
Cell Contractility and Implications for
CardiacDysfunctioninPatients with
SepticShock
Myocardial dysfunction is common in patients with sepsis
and is associated with high risk to develop multiorgan failure
and high mortality rate [76–78]. Septic cardiomyopathy is
characterizedbyreversiblebiventriculardilatation,decreased
ejection fraction, and impaired response to ﬂuid resuscita-
tion and catecholamine stimulation [76–78]. Although also
intrinsic cardiac factors have been implicated in this com-
plex condition [76–78], the causal role of circulating factors
has been extensively studied [77–79], following the obser-
vation that serum from patients with septic shock decreases
myocyte contractile function and that this eﬀect correlates
with the reduction of the patient’s left ventricular ejection
fraction [80]. A pivotal role for TNF-α and IL-1β in medi-
ating this depressant activity has clearly emerged from
subsequent studies [81]. Each individual cytokine, although
at supraphysiological concentrations, as well as the combina-
tion of the two at concentrations similar to those measured
in the bloodstream of septic patients, is able to reproduce
in vitro the depressant eﬀect of septic serum [82]. This re-
sponse is mainly mediated by the production of nitric oxide
(NO)andcyclicguanosinemonophosphate(cGMP)[83],al-
though also NO-independent mechanisms have been in-
volved [84].
No data on the potential contribution of TPO to myocar-
dial depression during sepsis was available at the time. We
therefore planned an experimental in vitro study to inves-
tigate whether TPO aﬀects myocardial contractile function
and contributes to the myocardial depressing activity of sep-
tic shock serum [85].
A ﬁrst original result of this study was the demonstration
of the presence of the TPO-receptor c-Mpl in the rat heart by
RT-PCRandimmunoblottingandinhumanmyocardiumby
immunoblotting [85]. Since endothelial cells express c-Mpl
[7], we studied the presence of c-Mpl also in cultured cardi-
omyocytes, deﬁnitely showing that they express c-Mpl on the
cellular surface, as also conﬁrmed by confocal microscopy
[85].
We then evaluated the eﬀects of TPO on myocardial
contractility in vitro and found that TPO did not directly
modify the contractile force of isolated rat papillary muscle,
but blunted the enhancement of contractile force induced
by epinephrine (EPI) in both papillary muscle and isolated
heartpr eparations[85].WepreviouslyobservedsimilarTPO
eﬀects in other experimental settings, where TPO exerts no
direct action per se, but rather ampliﬁes the eﬀects of other
biological mediators, in particular when we studied platelet
aggregationandmonocyte-plateletinteractioninresponseto
ADP and EPI [30], or the production of oxygen free rad-
icals by polymorphonuclear leukocytes challenged with
fMLP [86].
The speciﬁcity of TPO eﬀect was assessed by inhibiting
the biological activity of TPO using a TPOR-Fc chimera,
which completely abrogated the eﬀects exerted by TPO on6 Mediators of Inﬂammation
EPI-induced cardiac contractility, whereas it did neither alter
the contractile force of papillary muscle or isolated heart nor
inﬂuencetheirresponsivenesstobeta-adrenergicstimulation
[85].
The occurrence of myocardial depression in septic shock
is a well-documented phenomenon, which is associated with
high mortality rate [76–78]. Interestingly, the major patho-
genic mechanisms of septic cardiac dysfunction include both
alterations of adrenergic response and the eﬀects of humoral
mediators [76–79]. Myocardial hyporesponsiveness to cate-
cholamines (including decreased chronotropy and inotropy)
has been shown in several endotoxic models of septic shock
[87, 88], as well as in human septic shock [89, 90]. This eﬀect
has been related to disruption of β-adrenergic signal trans-
duction in cardiomyocytes due to both NO-dependent and
-independent mechanisms [84], analogously to what was
reported for ischemia/reperfusion injury [91–93]. Our re-
sults suggest that also TPO may inﬂuence the contractile
response elicited by EPI stimulation by aﬀecting adrenergic
signal transduction [85]. Moreover, the results obtained by
using speciﬁc pharmacological inhibitors on isolated rat
papillary muscles show that TPO action is mediated by the
activation of the PI3K-Akt1-NO Synthase-Guanylyl Cyclase
pathway, which leads to the production of NO as ﬁnal medi-
ator [85]. We have also shown that TPO directly induces
the phosphorylation of Akt1 in H9C2 cardiomyocytes and
isolated papillary muscles [85].
Evidence of a circulating myocardial depressant sub-
stance in the serum of septic shock patients was ﬁrst demon-
strated by Parrillo et al. [80]. Subsequent studies indicated
TNF-α and IL-1β as the pivotal mediators inducing cardiac
depression in sepsis [82] and other disease conditions [94,
95]. On the basis of the recent reports of elevated TPO levels
insepsis[26–29,68–72],wehypothesizedthatTPOmaycon-
cur to depress myocardial contractility during sepsis. We ob-
served that pretreatment of serum samples with the TPOR-
Fc chimera completely prevented the decrease in contractile
force-inducedbyhumansepsisshockserumalone,whereasit
had no eﬀect on serum of healthy subjects [85]. In addition,
we found that the negative inotropic eﬀect of both TNF-α
and IL-1β was signiﬁcantly enhanced by the addition of TPO
[85]. Moreover, TPOR-Fc chimera completely prevented the
decrease in contractile force induced by addition of TPO to
TNF-α or IL-1β, whereas it did not modify the contractile
responses induced by these cytokines alone [85]. The results
obtained strongly suggest that high levels of circulating TPO
in patients with sepsis may favor the occurrence of myo-
cardial depression in cooperation with TNF-α and IL-1β.
In conclusion, we showed in this study that TPO nega-
tively modulates myocardial contractility by stimulating its
receptor c-Mpl on cardiomyocytes and the subsequent pro-
duction of NO [85]. In addition, TPO mediates the cardio-
depressant activity exerted in vitro by serum of septic shock
patients,whichisindeedcompletelyabrogatedbytheTPOR-
Fc chimera [85]. Finally, TPO cooperates with TNF-α and
IL-1β in depressing cardiac contractility [85]. Therefore, our
results suggest that TPO may have a relevant role in modu-
lating cardiac inotropy in septic shock by aﬀecting the two
major pathogenic mechanisms described: (a) by inﬂuencing
adrenergic receptor signal transduction; (b) by cooperating
with circulating mediators known to reduce myocardial con-
tractility, namely TNF-α and IL-1β.
7. Characterization of Thrombopoietin as a
Physiological Regulator of Coronary Flow
We have previously shown that human umbilical cord vein-
derived endothelial cells (HUVECs) expressed the TPO re-
ceptor c-Mpl and that TPO activates HUVECs in vitro,a s
indicated by directional migration, synthesis of platelet-
activating factor and IL-8, and phosphorylation of STAT1
and STAT5B [96]. Others have shown that speciﬁc murine
liver EC (LEC-1) located in the hepatic sinusoids coexpresses
TPO and its receptor, c-Mp, and that TPO has a proliferative
eﬀectonLEC-1[97].Furthermore,stimulationwithTPOin-
duced secretion of proinﬂammatory cytokines (i.e., IL-1β,
IL-6, TNF-α) from LEC-1, some of which cooperate with
TPO in sustaining the proliferation of these cells [98].
Based on these data, we sought to investigate the poten-
tial role of TPO in coronary ﬂow modulation and to deter-
mine the mechanisms involved.
The expression of TPO receptor c-Mpl and the TPO-
dependent eNOS phosphorylation (PSer1179) were showed on
cardiac-derived normal human microvascular endothelial
cells (HMVEC-C) by Western blot analysis [99]. While TPO
(10–200pg/mL) did not modify coronary ﬂow (CF) under
basal conditions, it reduced the coronary constriction caused
by endothelin-1 (ET-1; 10nM) in a dose-dependent manner
[99]. This eﬀect was blocked by both Wortmannin (100nM)
and L-NAME (100nM); on HMVEC-C, TPO induced eNOS
phosphorylation through a Wortmannin sensitive mecha-
nism [99]. Our data suggest a potential role of TPO as a
physiological regulator of CF. By acting on speciﬁc receptors
present on endothelial cells, TPO may induce PI3K/Akt-
dependent eNOS phosphorylation and NO release.
8. Effects of Thrombopoietin Treatment on
MyocardialCellViabilityandCardiac
Function in Experimental Models of
MyocardialIschaemia-ReperfusionInjury
andHeart Failure
Recent experimental studies by other groups reported results
apparently not consistent with ours [100–102].
Li and colleagues [100], based on the rationale that TPO
possesses antiapoptotic functions mediated by the Akt pro-
survivalaxisinhematopoietic stemcellsandmegakaryocytes
[103,104],hypothesizedthatTPOmayprotectagainstcardi-
otoxicityinducedbydoxorubicin.Intheirstudy,theyshowed
that TPO exerts antiapoptotic activity in two diﬀerent in
vitro cellular models, namely, the fetal rat cardiomyocyte cell
line H9C2 and spontaneously beating primary neonatal rat
cardiomyocytes [100]. Moreover, TPO was able to preserve
cardiacfunctions,includingheartrate,fractionalshortening,
and cardiac output, evaluated by echocardiography, inMediators of Inﬂammation 7
interaction
PLTs
ECs
Cardiomyocytes
thrombosis organ failure
Burn injury,
severe sepsis,
septic shock
plaque instability
plaque progression
Acute coronary
syndrome
(HUVECs)
injury
cardiotoxicity
Septic shock
TPO/c-Mpl
↑PLT activation
↑PLT -MØ adhesion
↑Directional migration
↑Angiogenesis
↑Synthesis of PAF and IL-8
↑Proliferation (hepatic sinusoid ECs)
↑eNOS phosphorylation
↑NO release
(cardiac-derived
microvascular ECs)
↓Contractility (NO-mediated,
in cooperation with TNF-α and IL-1β)
↓Apoptosis
↑Microvascular
↑Atherosclerotic
↑Atherosclerotic
↑Progression to
Doxorubicin-induced
Ischemia-reperfusion
Figure 1: Schematic representation of TPO/c-Mpl functions in vascular system. PLTs = platelets; ECs = endothelial cells; MØ = monocytes;
PAF = platelet-activating factor; IL-8 = interleukin-8; HUVECs = human umbilical vein-derived endothelial cells; NO = nitric oxide; TNF-α
= tumor necrosis factor-α;I L - 1 β = interleukin-1β.
aninvivomodelofdoxorubicin-inducedacutecardiotoxicity
[100].
More recently, the same research group extended their
previous results by studying cardiac damage in two diﬀerent
rat models of acute- and chronic-doxorubicin treatment
[102]. In both models TPO treatment led to signiﬁcant
improvements of fractional shortening, cardiac output, and
morphologic parameters [102]. In the acute-doxorubicin
model,microarrayandnetworkanalysesshowedthatcardiac
damage was associated with changes in a large cohort of gene
expressions, of which many were inversely regulated by TPO,
including modulators of signal transduction, ion transport,
antiapoptosis, protein kinase B/p42/p44 extracellular signal-
regulated kinase (AKT/ERK) pathways, cell division, and
contractile protein/matrix remodeling [102]. Many of these
regulations also occurred in the animals chronically treated
with doxorubicin, in which TPO treatment reduced mor-
phological damage and cardiomyopathy score, and increased
AKT phosphorylation of heart tissues [102]. TPO was also
shown to increase the formation of endothelial progenitor
cell (EPC) colonies in their bone marrow [102]. The con-
clusions of the authors suggest that TPO-induced cardiac
protection from acute- and chronic-doxorubicin damages
may be mediated by multifactorial mechanisms including
AKT- and ERK-associated restoration of regulatory gene ac-
tivities critical for normal heart function [102].
In another recent study, Baker and colleagues demon-
strated that TPO treatment immediately before ischaemia
reduced myocardial necrosis, apoptosis, and decline in ven-
tricular function following ischaemia/reperfusion both in
vitro in the rat isolated heart and in vivo [101]. This TPO
eﬀect is concentration and dose dependent with an optimal
concentration of 1.0ng/mL in vitro and an optimal dose of
0.05μg/kg iv in vivo [101]. Increased resistance to injury
from myocardial ischaemia/reperfusion conferred by TPO
hasbeenshowntobemediatedbyJAK-2,p42/44MAPK,and
KATP channels [101].
9. Discussion and Conclusions
Wehavenoclearexplanationforthediscrepancybetweenthe
results summarised in the last paragraph [100–102]a n do u r s
[85], although the diﬀerent experimental models, together
with the concentrations used, well above the physiological
range, may, at least partially, justify these results.
Inourstudy[85]weevaluatedindeedTPOcardiaceﬀects
at doses analogous to those measured in human pathology,
in particular during septic shock [29], whereas, for instance,
Li and colleagues used TPO concentrations as high as
50ng/mLor100ng/mL[100],whicharecommonlyreported
as eﬀective in promoting hematopoietic cells in culture
[105, 106]. Moreover, in our study [85] we focused on the8 Mediators of Inﬂammation
acute changes induced by TPO pretreatment on EPI-stim-
ulated myocardial contractility in a time frame in which
apoptosis could diﬃcultly take place, thus making it diﬃcult
to compare ours with the results published by others. More
generally, all these studies were performed in rodent in vivo
models; therefore we have to be cautious in the eventual
transfer of the results to the pathophysiology of human dis-
eases. For instance, the experimental model of doxorubicin-
induced acute cardiotoxicity chosen [107, 108]d o e sn o t
closely mimic the chronic cardiomyopathy observed in clin-
ical situations during which repeated smaller doses of doxo-
r u b i c i na r eg i v e no v e rap e r i o do ft i m e ,a sr e p o r t e db yt h e
same authors [100]. Finally, and most important, although
it is well known that TPO primes the activity of other
mediators on important biological eﬀects in mature platelets
and other cell types [30–32, 86], previously reported results
were obtained in controlled experimental conditions, in
which only the eﬀects of TPO alone and at high doses were
considered, while the combined eﬀects of the administration
of TPO with other soluble mediators were not evaluated
[100–102]. On the contrary, we studied the eﬀects of TPO
contained in the plasma samples of patients with diﬀerent
pathological conditions [25, 64, 72, 85], and we were able
to show the contribution of TPO to the biological eﬀects
studied by selectively inhibiting TPO activity with a TPOR-
FC chimeric protein synthesized in our laboratory [25, 64,
72, 85]. Moreover, we investigated the eﬀects of TPO on
myocardial contractility at physiologic concentrations and
in association either with an adrenergic stimulus (EPI) or
the main cytokines known to depress myocardial activity in
septic shock, that is, TNF-α and IL-1β [85].
Therefore, our ﬁndings stress the importance of careful
evaluation of the cardiovascular eﬀects of TPO in vivo,e s p e -
cially in the clinical setting of diseases, such as heart failure
and septic shock, whose pathogenesis is complex and
involves the activation of a cascade of soluble mediators
(Figure 1). Interestingly, large-scale clinical trials evaluating
theeﬀectsofmonoclonalantibodiesagainstTNF-αinchron-
ic heart failure patients gave rather disappointing outcomes
[131, 132], suggesting that counterbalancing this cytokine
alone may not be suﬃcient [133]. The individuation of TPO
as an additional molecular target may provide clue for the
development of new therapeutic interventions for the treat-
ment of patients with sepsis-associated cardiac dysfunction
and eventually chronic heart failure. Interestingly, several
recent studies proposed also new experimental therapeutic
approaches to various cardiac diseases based on the modu-
lation of the inﬂammatory and prothrombotic states which
are often associated with their development and progression
[134–136]. Moreover, a careful and complete evaluation of
the biological eﬀects of TPO in vivo, in particular for what
concerns cardiovascular consequences, needs to be envis-
aged.
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